Last reviewed · How we verify

NCT03320811: DGP-CeliacDis

Interpretation of Serological Tests in the Diagnosis of Celiac Disease: Anti-deamidated Gliadin Peptide Antibodies Revisited

Completed Last updated 25 October 2017
What this trial tests

trial testing Data record in Celiac Disease in 2,026 participants. Completed in 1 January 2016.

Timeline
1 January 2015
Primary endpoint
1 September 2015
1 January 2016

Quick facts

Lead sponsorCHU de Reims
StatusCompleted
Study typeOBSERVATIONAL
Enrollment2,026
Start date1 January 2015
Primary completion1 September 2015
Estimated completion1 January 2016
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

CHU de Reims — full company profile →

Who can join

Eligibility, any sex, with Celiac Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Celiac disease is an autoimmune disorder characterized by a chronic inflammation of the small bowel mucosa, triggered by the ingestion of gluten-containing grains. The diagnosis of celiac disease was initially based on duodenal biopsies obtained from upper endoscopy. Since 1990, the availability of serological tests has contributed to a different perception of the disease. Serological testing is now considered fundamental for celiac disease screening, even if duodenal biopsies remain the gold standard. Celiac markers usually include anti-TG2 antibodies, anti-endomysium antibodies, anti-gliadin antibodies and anti-reticulin antibodies. Recently, several studies showed that deamidated products of gliadin may enhance T-cell stimulatory activity and improve the reactivity of anti-gliadin antibodies. Thus, detection of anti-deamidated gliadin peptide antibodies has been introduced into the wide spectrum of serological tests for celiac disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Data record

Trials testing the same drug.

Other recruiting trials for Celiac Disease

Currently open trials in the same condition.

Other CHU de Reims trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03320811.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing